BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37855289)

  • 1. Tumor Organoid as a Drug Screening Platform for Cancer Research.
    Mahbubi R; Yousefi N; Hamidieh AA; Gholizadeh F; Sisakht MM
    Curr Stem Cell Res Ther; 2023 Oct; ():. PubMed ID: 37855289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.
    Zhou Z; Cong L; Cong X
    Front Oncol; 2021; 11():762184. PubMed ID: 35036354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
    Taverna JA; Hung CN; Williams M; Williams R; Chen M; Kamali S; Sambandam V; Hsiang-Ling Chiu C; Osmulski PA; Gaczynska ME; DeArmond DT; Gaspard C; Mancini M; Kusi M; Pandya AN; Song L; Jin L; Schiavini P; Chen CL
    Lung Cancer; 2024 Apr; 190():107533. PubMed ID: 38520909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
    Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
    Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients.
    Zou Z; Lin Z; Wu C; Tan J; Zhang J; Peng Y; Zhang K; Li J; Wu M; Zhang Y
    Adv Sci (Weinh); 2023 Sep; 10(27):e2302640. PubMed ID: 37485650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine.
    Novelli G; Spitalieri P; Murdocca M; Centanini E; Sangiuolo F
    Front Cell Dev Biol; 2022; 10():1059579. PubMed ID: 36699015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer organoids: A platform in basic and translational research.
    Ma X; Wang Q; Li G; Li H; Xu S; Pang D
    Genes Dis; 2024 Mar; 11(2):614-632. PubMed ID: 37692477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
    Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera BarĂ³n C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
    J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal Organoids: A Next-Generation Platform for High-Throughput Drug Discovery.
    Zhao H; Yan F
    Stem Cell Rev Rep; 2024 Feb; 20(2):495-508. PubMed ID: 38079086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
    Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
    Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC).
    Lee SY; Cho HJ; Choi J; Ku B; Moon SW; Moon MH; Kim KS; Hyun K; Kim TJ; Sung YE; Hwang Y; Lee E; Ahn DH; Choi JY; Lim JU; Park CK; Kim SW; Kim SJ; Koo IS; Jung WS; Lee SH; Yeo CD; Lee DW
    J Exp Clin Cancer Res; 2023 Nov; 42(1):309. PubMed ID: 37993887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
    Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response.
    Piro G; Agostini A; Larghi A; Quero G; Carbone C; Esposito A; Rizzatti G; Attili F; Alfieri S; Costamagna G; Tortora G
    Front Med (Lausanne); 2021; 8():793144. PubMed ID: 35004765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening.
    Cui R; Duan H; Hu W; Li C; Zhong S; Liang L; Chen S; Hu H; He Z; Wang Z; Guo X; Chen Z; Xu C; Zhu Y; Chen Y; Sai K; Yang Q; Guo C; Mou Y; Jiang X
    J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38656317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived organoid (PDO) platforms to facilitate clinical decision making.
    Liu L; Yu L; Li Z; Li W; Huang W
    J Transl Med; 2021 Jan; 19(1):40. PubMed ID: 33478472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers.
    Yu YY; Zhu YJ; Xiao ZZ; Chen YD; Chang XS; Liu YH; Tang Q; Zhang HB
    Biomark Res; 2022 Oct; 10(1):73. PubMed ID: 36207749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research.
    Yan S; He Y; Zhu Y; Ye W; Chen Y; Zhu C; Zhan F; Ma Z
    Front Cell Dev Biol; 2024; 12():1384450. PubMed ID: 38638528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.